Alprostadil infusion in patients with dry age related macular degeneration: A randomized controlled clinical trial

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 803-812

  Augustin, Albert J ^a   Diehm, Curt ^b   Grieger, Frank ^c   Bentz, Juergen ^c  

^a Klinikum Karlsruhe   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UCB PHARMA   (Belgium)

Author keywords

Age related macular degeneration; Alprostadil; Prostaglandin E1; Therapy; Visual acuity

Indexed keywords

PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY TEMPERATURE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY AGE RELATED MACULAR DEGENERATION; ERYTHROCYTE COUNT; FEMALE; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; PHLEBITIS; PROSPECTIVE STUDY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; VISUAL ACUITY; VISUAL DISORDER;

AGED; AGED, 80 AND OVER; ALPROSTADIL; AUSTRIA; DOUBLE-BLIND METHOD; FEMALE; GEOGRAPHIC ATROPHY; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OPHTHALMOSCOPY; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; VISUAL ACUITY;

EID: 84879125778     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.794782     Document Type: Article

References (35)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51
2. Klein R, Klein BE, Lee KE, et al. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol 2006;142:532-49
3. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration and emerging pathogenetic and therapeutic concepts. Ann Med 2006;38:450-71
4. Klein R, Chou CF, Klein BE, et al. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011;129:75-80
5. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72
6. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. Arch Ophthalmol 2001;119:1417-36
7. Augustin AJ, Schmidt-Erfurth U. Kritische Worte zur ARED-Studie. Ophthalmologe 2002;99:299-300
8. Pulido JS; Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double-masked, placebo-controlled study of rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc 2002;100:85-106
9. Koss MJ, Kurz P, Tsobanelis T, et al. Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration. Dry AMD treatment with Rheopheresis Trial-ART. Graefes Arch Clin Exp Ophthalmol 2009;247:1297-306
10. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial disease stages III and IV. Vasa 2004;33:137-44
11. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 2005;56:409-16
12. Heidrich H, Breddin K, Rudofsky G, Scheffer P. Cardiopulmonary effects and safety of prostaglandin E1: a review. Int J Angiol 1994;3:160-8
13. Schror K, Hohlfeld T. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease. Vasa 2004;33:119-24
14. Hyman L, Schachat AP, He Q. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 2000;118:351-8
15. Age-Related Eye Disease Study Group. Risk factors associated with age-related macular degeneration: a case control study in the age related eye disease study. Age-Related Eye Disease Study Report Number 3. Ophthalmology 2000;107:2224-32
16. Klein R, Klein BE, Tomany SC, Cruickshanks KJ. The association of cardiovascular disease with the long-term incidence of age-related maculopathy. Ophthalmology 2003;110:1273-80
17. Hogg RE, Woodside JV, Gilchrist SE, et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 2008;115:1046-52
18. Tomany SC, Wang JJ, van Leeuwen R, et al. Risk factors for incidentage-related macular degeneration. Pooled findings from 3 continents. Ophthalmology 2004;111:1280-7
19. Delcourt C, Michel F, Colvez A, et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 2001;8:237-49
20. Chaine G, Hullo A, Sahel J, et al. Case-control study of the risk factors for age related macular degeneration. Br J Ophthalmol 1998;82:996-1002
21. Grunwald JE, Harispasad S, DuPont JC. Effect on aging on foveolar choroidal circulation. Arch Ophthalmol 1998;116:150-4
22. Grunwald JE, Harisprasad S, DuPont JC. Foveolar choroidal blood flow in age-related macular degeneration. Invest Opthalmol Vis Sci 1998;39:385-90
23. Grunwald JE, Metelitsina TI, Dupont JC, et al. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-8
24. Metelitsina TI, Grunwald JE, DuPont JC, et al. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:358-63
25. Xu W, Grunwald JE, Metelitsina TI, et al. Assocation of risk factors for choroidal neovascularization in AMD with decreased foveolar choroidal circulation. Am J Ophthalmol 2010;150:40-47.e2
26. Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol 2011;95:14-25
27. Karagianni N, Adamis AP. The case for complement and inflammation in AMD: open questions. Adv Exp Med Biol 2010;703:1-7
28. Heidrich H, Harnisch JP, Ranft J. PGE1 bei seniler Maculadegeneration. Pilot-Studie. Klin Monatsbl Augenheilkd 1989;194:282-4
29. Ladewig MS, Ladewig K, Güner M, Heidrich H. Prostaglandin E1 infusion therapy in dry age-related macular degeneration. Prostaglandins Leukot Essent Fatty Acids 2005;72:251-6
30. Ferris FL, Bailey I. Standardizing the measurement of visual acuity for clinical research studies. Ophthalmology 1996;103:181-2
31. Ferris FL, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6
32. Kaiser PK. Prospective evaluation of visual acuity assessement: a comparison of Snellen vs. ETDRS charts in clinical practice (an AOS thesis). Trans Am Ophthalmol Soc 2009;107:311-24
33. Creutzig A, Bullinger M, Cachovan M, et al. Improvement in the quality of life after i.v. PGE1 therapy for intermittent claudication. Vasa 1997;26:122-7
34. Yehoshua Z, Rosenfeld PJ, Gregori G, Penha F. Spectral domain optical coherence tomography imaging of dry age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2010;41:S6-S14
35. Augustin A. Optical coherence tomography imaging and quantitative assessment for monitoring dry age-related macular degeneration. Eur Ophthalmic Rev 2012;6:72-7